Lavipharm S.A. Share Price

LAVI

GRS246003008

Pharmaceuticals

Delayed Athens S.E. 06:55:15 07/09/2026 pm IST			5-day change	1st Jan Change
1.592 ^EUR	-1.12%		-3.40%	+64.12%

25/06	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI
28/05	Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y	RE

Lavipharm SA is a Greece-based pharmaceutical and healthcare company engaged in the research and development of drug delivery solutions and the commercialisation of pharmaceutical, over-the-counter (OTC) and related healthcare products. It is active in the provision of prescription medicines, OTC products and food supplements, supported by integrated activities across research and development, manufacturing and commercial operations. It maintains a portfolio focused primarily on therapeutic areas including cardiology, central nervous system disorders, urology, oncology and chronic pain, supplying solutions designed for healthcare professionals and patients. The Company operates in both domestic and international markets and combines product development capabilities with market access and distribution activities, while acting as the parent entity of the Lavipharm Group through which its broader operations are conducted.

Employees

285

Sector

Pharmaceuticals

Calendar

17/09 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
07/26/07	€1.592	-1.12%	19,524
04/26/04	€1.610	-0.62%	56,668
03/26/03	€1.620	-0.12%	24,809
02/26/02	€1.622	-1.10%	85,748
01/26/01	€1.640	-0.49%	36,306

Delayed Quote Athens S.E.

More quotes

Market Cap	27Cr 32Cr 26Cr 24Cr 44Cr 3.02TCr 44Cr 305.69Cr 118.62Cr 1.55TCr 119.99Cr 117.37Cr 4.99TCr	P/E 2024	14.9x	P/E 2025	27.9x
Enterprise Value	30Cr 35Cr 28Cr 26Cr 48Cr 3.31TCr 49Cr 335.35Cr 130.13Cr 1.7TCr 131.63Cr 128.75Cr 5.47TCr	EV / Sales 2024	3.07x	EV / Sales 2025	3.04x
Free-Float	39.31%	Yield 2024	2.52%	Yield 2025	-

25/06	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI
28/05	Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y	RE
28/05	Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
09/04	Lavipharm to acquire Durogesic pain patch rights from Janssen for $12.0 million	RE
19/03	Lavipharm SA FY 2025 earnings after tax EUR 6.0 million versus EUR 9.0 million year ago	RE
19/03	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
17/11	Lavipharm 9-month net profit down to EUR 3.5 million	RE
18/25/18	Lavipharm H1 adjusted EBITDA at EUR 7.7 million, up 29.4% Y/Y	RE
18/25/18	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/25/03	Lavipharm S.A. announces Annual dividend, payable on July 24, 2025	CI
15/25/15	Lavipharm Q1 Net Profit At EUR 1.6 Million, Up 46.8% YoY	RE
14/25/14	Lavipharm And Tikun Olam Europe Launch Joint Telemedicine Company	RE
19/25/19	Lavipharm FY 2024 Earnings After Tax EUR 9.0 Million Versus EUR 1.87 Million Year Ago	RE

03/09	Lavipharm S A : Announcement Appointment of Chief Manufacturing & Operations Officer	PU
11/06	Lavipharm S A : Announcement Appointment of Chief Quality Officer	PU
22/05	Lavipharm S A : IMPORTANT CORPORATE EVENTS	PU
07/11	Lavipharm S A : OTHER ANNOUNCEMENTS	PU
15/25/15	Lavipharm S A : ANNOUNCEMENT OF REGULATED INFORMATION - TRANSACTIONS NOTIFICATION	PU

1 day	-0.62%
1 week	-2.91%
Current month	-2.91%
1 month	+3.23%
3 months	+2.96%
6 months	+34.68%
Current year	+64.95%

1 week	1.58	1.67
1 month	1.53	1.69
Current year	0.94	1.74
1 year	0.76	1.74
3 years	0.58	1.74
5 years	0.35	2.22
10 years	0.16	2.22

Lavipharm S.A. Share Price

Stocks

LAVI

GRS246003008

Pharmaceuticals

Valuation : Lavipharm S.A.

Chart: Lavipharm S.A.

Latest news : Lavipharm S.A.

Press Releases : Lavipharm S.A.

Quotes and Performance

Price Extremes

Managers and Directors : Lavipharm S.A.

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Vassilis Baloumis DFI	Director of Finance/CFO	-	01/12/2021
Ligia Panaitescu CTO	Chief Tech/Sci/R&D Officer	-	-
Eleana Nikolopoulou CMP	Compliance Officer	-	-

Director	Title	Age	Since
James P. Christopoulos BRD	Director/Board Member	-	-
Minas G. Tanes CHM	Chairman	86	01/01/2021
Telemaque Jean Lavidas BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/02/25	Vassilis Baloumis	Buy	Chief Financial Officer	20,000	0.0119%
27/05/23	Thomas Tseronis	Sell		35,434	0.0189%
28/03/23	Vassilis Baloumis	Buy	Chief Financial Officer	23,455	0.0125%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LAVIPHARM S.A.	-0.62%	-2.91%	+98.27%	+140.96%	32Cr
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.21%	-4.52%	+19.86%	+67.25%	4.83TCr
OTSUKA HOLDINGS CO., LTD.	-2.49%	-4.24%	+38.37%	+110.97%	4.05TCr
CIPLA LIMITED	+0.72%	-1.01%	-9.49%	+11.66%	1.19TCr
ZYDUS LIFESCIENCES LIMITED	+3.29%	-0.38%	+14.58%	+82.76%	1.18TCr
KRKA, D. D.	+2.31%	0.00%	+26.67%	+146.30%	935.93Cr
GEDEON RICHTER	-0.94%	-3.27%	+22.35%	+38.27%	749.58Cr
ONO PHARMACEUTICAL CO., LTD.	-1.23%	-1.31%	+36.14%	-13.14%	737.27Cr
GLENMARK PHARMACEUTICALS LIMITED	+0.60%	-1.13%	+19.49%	+208.86%	728.46Cr
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.16%	-2.36%	-46.14%	+18.48%	518.68Cr
Average	+0.13%	-2.08%	+22.01%	+81.24%	1.49TCr
Weighted average by Cap.	-0.37%	-1.71%	+21.35%	+80.82%

	2024	2025
Net sales	5.29Cr 6.15Cr 4.98Cr 4.55Cr 8.51Cr 580.93Cr 8.54Cr 59Cr 23Cr 298.06Cr 23Cr 23Cr 960.21Cr	6.26Cr 7.27Cr 5.89Cr 5.38Cr 10Cr 686.68Cr 10Cr 70Cr 27Cr 352.32Cr 27Cr 27Cr 1.13TCr
Net income	89.82L 1.04Cr 84.51L 77.2L 1.44Cr 99Cr 1.45Cr 9.99Cr 3.88Cr 51Cr 3.92Cr 3.83Cr 162.89Cr	59.86L 69.56L 56.32L 51.45L 96.24L 66Cr 96.51L 6.66Cr 2.58Cr 34Cr 2.61Cr 2.56Cr 108.56Cr
Net Debt	2.83Cr 3.29Cr 2.67Cr 2.44Cr 4.56Cr 310.9Cr 4.57Cr 32Cr 12Cr 159.51Cr 12Cr 12Cr 513.87Cr	2.67Cr 3.1Cr 2.51Cr 2.29Cr 4.29Cr 292.66Cr 4.3Cr 30Cr 12Cr 150.16Cr 12Cr 11Cr 483.73Cr